Targeting the JAK/STAT Pathway in Inflammatory Diseases
PROGRAM DESCRIPTION Rheumatoid arthritis (RA) and inflammatory bowel disease (IBD) are chronic, systemic, autoimmune disorders characterized by inflammatory processes. There are numerous classes of therapies available to treat RA and …
Rheumatoid arthritis (RA) and inflammatory bowel disease (IBD) are chronic, systemic, autoimmune disorders characterized by inflammatory processes. There are numerous classes of therapies available to treat RA and IBD, and some patients achieve low disease activity or remission, yet a proportion of patients exhibits an inadequate response and/or discontinues therapy due to tolerability. As such, investigations into new targets and therapies, such as the janus kinase (JAK) inhibitors, continue. The introduction of JAK inhibitors further contributes to a growing armamentarium of therapies for these immune-mediated inflammatory diseases. Evolving strategies for employing the JAK inhibitors present a decision-making challenge to clinicians who treat these patients.Bring this content to your institution! To educate your staff and earn additional CME credit, please contact Michelle Forcier at 773-714-0705 x118.
Upon completion of this activity, participants will be able to:Discuss the role of the JAK/STAT signaling pathway in the inflammation and disease progression of immune-mediated inflammatory diseasesEvaluate the use of JAK inhibitors in immune-mediated inflammatory diseases such as RA and IBDInterpret clinical trial efficacy and safety data of JAK inhibitors under investigation across inflammatory diseasesOutline approaches to educating patients on the role of JAK inhibition, including efficacy and safety data
I'm interested in this
Share with others
Write the first review
Share with others